New combo therapy tackles tough cancers in early trial
NCT ID NCT07407985
First seen Feb 17, 2026 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This early-stage trial tests a new cell treatment (GK01) combined with an immunotherapy drug (PD-1 antibody) in 15 people with advanced solid tumors that have spread or come back. The main goal is to see if the combination is safe and to measure how the body processes it. Researchers will also look for signs that the tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.